Drugs/Recall·openFDA/drug

Bell Pharmaceuticals, Inc — Class II: LEADER, Carbamide Peroxide 6.5%, 0.5 Fl Oz (15 mL), a) Kit -1 RUBBER BULB SYRINGE, 0.5 FL

MediumPublished Jul 22, 2026· AI-analyzed Jul 27, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Bell Pharmaceuticals, Inc. has initiated a Class II recall for LEADER Carbamide Peroxide 6.5% ear drops due to the product being subpotent, exhibiting a low pH and an assay value of approximately 0.6% compared to the expected range of 6-7%.

Who it affects

This affects Bell Pharmaceuticals, Inc., the distributor Cardinal Health, and quality and compliance personnel responsible for OTC ear care products.

Why it matters

A significant reduction in active ingredient assay (approximately 10% of the expected concentration) suggests potential stability or formulation failures. For regulatory professionals, this underscores the importance of pH monitoring in peroxide-based solutions, as deviations can lead to rapid degradation of the active pharmaceutical ingredient.

Practical takeaway

Quality units should review stability data and pH specifications for carbamide peroxide formulations to ensure long-term potency. Regulatory and procurement teams managing Cardinal Health-distributed products should verify inventory against the specified NDC numbers (70000-0689-1 and 70000-0688-1).

FDA source material

Class II. Reason: SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).. Product: LEADER, Carbamide Peroxide 6.5%, 0.5 Fl Oz (15 mL), a) Kit -1 RUBBER BULB SYRINGE, 0.5 FL OZ DROPS, (NDC 70000-0689-1); b) 1 bottle (NDC 70000-0688-1), DIST. BY CARDINAL HEALTH, DUBLIN, OH 43017.. Firm: Bell Pharmaceuticals, Inc (Belle Plaine MN United States). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.